Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA.
Department of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA.
Int J Cardiol. 2018 Dec 15;273:22-28. doi: 10.1016/j.ijcard.2018.08.020. Epub 2018 Aug 16.
Coronary microvascular obstruction (MVO) in infarct-related artery (IRA) territory has been associated with worse cardiovascular outcomes in patients presenting with ST-segment elevation myocardial infarction. However, the prognostic value of non-IRA MVO in this patient population remains unknown.
One hundred ninety nine patients presenting to our institution with STEMI were enrolled. All patients underwent primary percutaneous coronary intervention per institutional STEMI protocol followed by a cardiac MRI within 1 week of presentation and the IRA and non-IRA MVO segments were determined. All cause death, recurrent myocardial infarction, hospitalization for heart failure, and ventricular tachycardia were counted as major adverse cardiovascular events (MACE). Patients with non-IRA MVO had lower composite MACE free survival at 6 months (HR 2.15, 95% CI, 1.06-4.35; p = 0.029) compared to those without non-IRA MVO. In a sub-analysis of patients with multi vessel disease (MVD), patients with non-IRA MVO also had lower composite MACE-free survival at 6 months as compared to those without non-IRA MVO (HR 2.47, 95% CI, 1.02-5.97; p = 0.037). Non-IRA MVO continued to be predictive of MACE in a cox proportional hazards model adjusting for additional prognostic factors using inverse probability weighting (p = 0.007). Non-IRA MVO was more prevalent in patients with LAD culprit vessel STEMI rather than those with RCA or Circumflex culprit vessels (p < 0.001).
Patients presenting with STEMI and non-IRA MVO have significantly lower MACE free survival at 6 months as compared to those without non-IRA MVO.
梗死相关动脉(IRA)区域的冠状动脉微血管阻塞(MVO)与ST 段抬高型心肌梗死患者的心血管不良结局相关。然而,在该患者人群中,非 IRA MVO 的预后价值仍不清楚。
199 例因 ST 段抬高型心肌梗死就诊于我院的患者被纳入研究。所有患者均按照院内 ST 段抬高型心肌梗死方案行直接经皮冠状动脉介入治疗,随后在发病后 1 周内行心脏 MRI,并确定 IRA 和非 IRA MVO 节段。全因死亡、复发性心肌梗死、心力衰竭住院和室性心动过速被计为主要不良心血管事件(MACE)。与无非 IRA MVO 的患者相比,有非 IRA MVO 的患者在 6 个月时复合 MACE 无事件生存率更低(HR 2.15,95%CI,1.06-4.35;p=0.029)。在多血管疾病(MVD)患者的亚组分析中,与无非 IRA MVO 的患者相比,有非 IRA MVO 的患者在 6 个月时复合 MACE 无事件生存率也更低(HR 2.47,95%CI,1.02-5.97;p=0.037)。在使用逆概率加权法调整其他预后因素的 Cox 比例风险模型中,非 IRA MVO 仍然是 MACE 的预测因素(p=0.007)。在 LAD 罪犯血管 ST 段抬高型心肌梗死患者中,非 IRA MVO 的发生率明显高于 RCA 或 Circumflex 罪犯血管 ST 段抬高型心肌梗死患者(p<0.001)。
与无非 IRA MVO 的患者相比,ST 段抬高型心肌梗死且伴有非 IRA MVO 的患者在 6 个月时的 MACE 无事件生存率显著降低。